Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metastatic liver disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,901 result(s) found for: Metastatic liver disease. Displaying page 1 of 96.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-005197-51 Sponsor Protocol Number: 14650 Start Date*: 2008-07-24
    Sponsor Name:The Netherlands Cancer Institute/ Antoni van Leeuwenhoek hospital [...]
    1. The Netherlands Cancer Institute/ Antoni van Leeuwenhoek hospital
    2. Radboud University Nijmegen Medical Center
    Full Title: Accelerated growth of synchronous colorectal liver metastases: effects of neo-adjuvant therapy
    Medical condition: synchronous liver metastases in patients with the primary colorectal tumour in situ
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024700 Liver metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002105-44 Sponsor Protocol Number: ML20982 Start Date*: 2008-07-02
    Sponsor Name:Military Medical Academy Hospital for Active Treatment, Sofia
    Full Title: Open – label, non randomized clinical study of Neoadjuvant chemotherapy with FOLFIRI and Avastin in patients with non-resectable liver metastases of colorectal cancer
    Medical condition: Metastatic (liver metastases) colorectal cancer, with no prior chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024700 Liver metastases LLT
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000628-24 Sponsor Protocol Number: MO16/053 Start Date*: 2018-01-12
    Sponsor Name:University of Leeds
    Full Title: A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver m...
    Medical condition: Colorectal cancer liver metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007095 Cancer of liver, secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-002214-17 Sponsor Protocol Number: NL78220.029.21 Start Date*: 2023-04-24
    Sponsor Name:Amsterdam University Medical Centers
    Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial
    Medical condition: Recurrent colorectal liver metastases
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024700 Liver metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005495-42 Sponsor Protocol Number: TIMP_in_mCRC Start Date*: 2012-04-10
    Sponsor Name:Kell Osterlind
    Full Title: Individualised first line chemotherapy in metastatic colo-rectal cancer (mCRC). Is plasma TIMP-1 a predictive factor for best choise of first line chemotherapy in mCRC?
    Medical condition: Metastatic colon or rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027457 Metastases to liver PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-006205-28 Sponsor Protocol Number: DMT_CRC_001 Start Date*: 2006-04-15
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Role of Erbitux plus a combination of CPT-11/5-fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy in patients with colorectal liver metastases
    Medical condition: Liver metastases from colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027457 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003288-31 Sponsor Protocol Number: TUD-CELIM2-050 Start Date*: 2012-06-04
    Sponsor Name:Technical University Dresden
    Full Title: Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in ras wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or...
    Medical condition: The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: - Cetuximab/FOL...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027457 Metastases to liver PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004245-42 Sponsor Protocol Number: 10078 Start Date*: 2006-09-07
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHARMACODYNAMIC STUDY OF ORAL MIRTOSELECT IN PATIENTS WITH SUSPECTED HEPATIC DISEASE
    Medical condition: Patients with operable liver metastases
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024700 Liver metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012115-18 Sponsor Protocol Number: IMP13617 Start Date*: 2010-03-22
    Sponsor Name:UMC Utrecht
    Full Title: Primovist enhanced MRI for the detection and evaluation of focal liver lesions
    Medical condition: All benign and malignant focal liver lesions e.g. colorectal liver metastases, HCC, haemangioma, adenoma, cysts, FNH.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10024658 Liver carcinoma LLT
    12.0 10027479 Metastatic liver carcinoma LLT
    12.0 10019827 Hepatocellular adenoma LLT
    12.0 10049010 Carcinoma hepatocellular LLT
    12.0 10019396 Hemangioma of liver LLT
    12.0 10048834 Polycystic liver disease LLT
    12.0 10052285 Focal nodular hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003028-22 Sponsor Protocol Number: RGT100-001 Start Date*: 2017-01-26
    Sponsor Name:Rigontec GmbH
    Full Title: A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors
    Medical condition: Advanced or recurrent tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020962 10065252 Solid tumor LLT
    20.0 100000020848 10024700 Liver metastases LLT
    20.0 100000020895 10024717 Liver tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003606-53 Sponsor Protocol Number: CA224106 Start Date*: 2022-06-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocell...
    Medical condition: Advanced/metastatic hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019238-29 Sponsor Protocol Number: 40091 Start Date*: 2013-06-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from w...
    Medical condition: Resectable liver metastases from wild type KRAS and NRAS colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024700 Liver metastases LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) GB (Completed) DE (Prematurely Ended) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004632-24 Sponsor Protocol Number: Start Date*: 2008-02-01
    Sponsor Name:ARTBC
    Full Title: OPTIMAL CONTROL OF LIVER METASTASES WITH INTRAVENOUS CETUXIMAB AND HEPATIC ARTERY INFUSION OF THREE-DRUG CHEMOTHERAPY IN PATIENTS WITH LIVER-ONLY METASTASES FROM COLORECTAL CANCER. A PHASE II TRIAL
    Medical condition: The primary objective of the study is to increase by 15% the complete macroscopic resection rate of predominantly liver metastases from metastatic colorectal cancer through combining systemic cetux...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023526-21 Sponsor Protocol Number: MO25515 Start Date*: 2011-03-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Estudio multicéntrico, abierto, de acceso expandido, de RO5185426 en pacientes con melanoma metastásico An open-label, multicenter expanded access study of RO5185426 in patients with metastatic me...
    Medical condition: Tratamiento de pacientes adultos con melanoma metastásico confirmado histológicamente, portador de la mutación BRAF V600 identificada por medio del test Cobas 4800 para mutaciones BRAF V600, en los...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) SE (Completed) NL (Completed) SI (Completed) GR (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed) SK (Completed) BE (Completed) BG (Completed) NO (Completed) PT (Completed) LV (Completed) FI (Completed) IT (Completed) DK (Completed) EE (Completed) LT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012655-26 Sponsor Protocol Number: HE 6A/09 Start Date*: 2010-07-13
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS
    Medical condition: Wild-type K-ras metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005422-76 Sponsor Protocol Number: CRAD001C24100 Start Date*: 2008-09-01
    Sponsor Name:PD Dr. Gerhard Treiber
    Full Title: Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An open label, stratified, single-arm phase II study of Bevacizumab and RAD001
    Medical condition: Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004380-40 Sponsor Protocol Number: CA209-76U Start Date*: 2020-11-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab
    Medical condition: The study population will include participants diagnosed with metastatic melanoma, advanced/metastatic urothelial carcinoma (mUC), advanced hepatocellular carcinoma (HCC) in Part 1, and metastatic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004505-29 Sponsor Protocol Number: 2676 Start Date*: 2008-05-15
    Sponsor Name:Royal Marsden NHS Trust
    Full Title: Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer
    Medical condition: Metastatic colorectal adenocarcinoma with metastases involving the liver only
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012010-52 Sponsor Protocol Number: mRCC Start Date*: 2009-08-04
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma
    Medical condition: Patient with previously untreated Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000144-18 Sponsor Protocol Number: CDKO-125a-010 Start Date*: 2017-08-01
    Sponsor Name:Tiziana Life Sciences Plc
    Full Title: Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients with Unresectable or Metastatic Hepatocellular Carcinoma
    Medical condition: Uunresectable or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 22:41:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA